COL2A1_HUMAN,G1092S,0.939,Gain of Loop (Pr = 0.27 | P = 0.03); Loss of Methylation at R1088 (Pr = 0.19 | P = 8.3e-03), ELME000085|ELME000147,-
COL2A1_HUMAN,Q1109P,0.293,-,-,-
COL2A1_HUMAN,P1124A,0.099,-,-,-
COL2A1_HUMAN,G1247A,0.183,-,-,-
COL2A1_HUMAN,G1247T,0.200,-,-,-
COL2A1_HUMAN,S1268N,0.135,-,-,-
COL2A1_HUMAN,W1293G,0.889,Altered Ordered interface (Pr = 0.29 | P = 0.03); Gain of B-factor (Pr = 0.29 | P = 5.2e-03); Altered Stability (Pr = 0.18 | P = 0.01); Altered Transmembrane protein (Pr = 0.10 | P = 0.04); Gain of Sulfation at Y1298 (Pr = 0.06 | P = 5.6e-03), None,-
COL2A1_HUMAN,K1294T,0.730,Altered Ordered interface (Pr = 0.23 | P = 0.05); Altered Transmembrane protein (Pr = 0.10 | P = 0.05); Gain of Catalytic site at W1299 (Pr = 0.10 | P = 0.04); Gain of Sulfation at Y1298 (Pr = 0.06 | P = 5.3e-03), ELME000085|ELME000220|PS00006,-
COL2A1_HUMAN,S1295P,0.942,Altered Transmembrane protein (Pr = 0.10 | P = 0.05); Loss of Catalytic site at W1299 (Pr = 0.10 | P = 0.04); Gain of Sulfation at Y1298 (Pr = 0.05 | P = 7.7e-03), ELME000085,-
COL2A1_HUMAN,S1295R,0.911,Altered Transmembrane protein (Pr = 0.10 | P = 0.05); Loss of Catalytic site at W1299 (Pr = 0.10 | P = 0.04); Gain of Sulfation at Y1298 (Pr = 0.05 | P = 8.0e-03), ELME000085|ELME000100|ELME000108|PS00016,-
COL2A1_HUMAN,M1317L,0.766,Altered Transmembrane protein (Pr = 0.31 | P = 1.3e-04); Altered Ordered interface (Pr = 0.29 | P = 0.03); Altered Metal binding (Pr = 0.26 | P = 0.02); Loss of Disulfide linkage at C1315 (Pr = 0.25 | P = 7.0e-03), None,-
COL2A1_HUMAN,S1338N,0.446,-,-,-
COL2A1_HUMAN,K1340D,0.770,Loss of B-factor (Pr = 0.27 | P = 0.03); Altered Transmembrane protein (Pr = 0.21 | P = 4.8e-03); Loss of GPI-anchor amidation at N1335 (Pr = 0.01 | P = 0.02), ELME000063|ELME000233|PS00005,-
COL2A1_HUMAN,S1341N,0.280,-,-,-
COL2A1_HUMAN,S1341T,0.192,-,-,-
COL2A1_HUMAN,E1343D,0.118,-,-,-
COL2A1_HUMAN,K1345R,0.488,-,-,-
COL2A1_HUMAN,P1368A,0.326,-,-,-
COL2A1_HUMAN,S1386A,0.338,-,-,-
COL2A1_HUMAN,K1394R,0.706,Altered Transmembrane protein (Pr = 0.28 | P = 4.9e-04); Altered Ordered interface (Pr = 0.25 | P = 0.02); Loss of Catalytic site at Y1391 (Pr = 0.11 | P = 0.04); Loss of Disulfide linkage at C1393 (Pr = 0.11 | P = 0.05); Altered Metal binding (Pr = 0.05 | P = 0.04), ELME000062|ELME000313,-
COL2A1_HUMAN,I1397V,0.370,-,-,-
COL2A1_HUMAN,A1404T,0.238,-,-,-
COL2A1_HUMAN,I1413V,0.288,-,-,-
COL2A1_HUMAN,V1449K,0.810,Gain of Relative solvent accessibility (Pr = 0.36 | P = 9.4e-04); Altered Ordered interface (Pr = 0.33 | P = 0.01); Altered Transmembrane protein (Pr = 0.30 | P = 1.5e-04); Altered Stability (Pr = 0.23 | P = 9.3e-03); Gain of Acetylation at K1444 (Pr = 0.20 | P = 0.04); Altered Disordered interface (Pr = 0.19 | P = 0.04), ELME000064|ELME000220|PS00006,-
COL2A1_HUMAN,S1454T,0.429,-,-,-
COL2A1_HUMAN,E1474D,0.277,-,-,-
COL2A1_HUMAN,E1474G,0.789,Altered Transmembrane protein (Pr = 0.37 | P = 1.9e-05); Altered Metal binding (Pr = 0.30 | P = 4.1e-03); Loss of Relative solvent accessibility (Pr = 0.30 | P = 9.8e-03); Altered Ordered interface (Pr = 0.28 | P = 0.04); Gain of Loop (Pr = 0.27 | P = 0.04); Loss of Catalytic site at D1469 (Pr = 0.18 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q1475 (Pr = 0.14 | P = 5.4e-03), ELME000117|PS00008,-
COL2A1_HUMAN,D1480E,0.582,Altered Ordered interface (Pr = 0.29 | P = 0.03); Altered Metal binding (Pr = 0.28 | P = 6.7e-03); Loss of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.24 | P = 1.7e-03); Gain of Pyrrolidone carboxylic acid at Q1475 (Pr = 0.15 | P = 4.7e-03); Gain of Catalytic site at E1476 (Pr = 0.10 | P = 0.04), None,-
COL2A1_HUMAN,G738D,0.951,Gain of Loop (Pr = 0.29 | P = 8.3e-03); Loss of B-factor (Pr = 0.26 | P = 0.04); Altered Metal binding (Pr = 0.24 | P = 0.02); Gain of O-linked glycosylation at S734 (Pr = 0.13 | P = 0.04), ELME000155,-
COL2A1_HUMAN,R719C,0.823,Loss of Methylation at R719 (Pr = 0.16 | P = 0.01), ELME000005|ELME000106|ELME000155,-
COL2A1_HUMAN,C1485G,0.968,Altered Metal binding (Pr = 0.49 | P = 4.0e-03); Gain of Intrinsic disorder (Pr = 0.48 | P = 2.3e-03); Altered Transmembrane protein (Pr = 0.21 | P = 4.6e-03), None,-
COL2A1_HUMAN,R1276C,0.682,Loss of Intrinsic disorder (Pr = 0.38 | P = 0.03); Altered Ordered interface (Pr = 0.29 | P = 0.03); Gain of Acetylation at K1277 (Pr = 0.23 | P = 0.02); Altered Transmembrane protein (Pr = 0.22 | P = 3.3e-03), ELME000102|ELME000162|ELME000239|ELME000337|PS00005,-
COL2A1_HUMAN,G888S,0.954,Loss of Methylation at R887 (Pr = 0.25 | P = 1.9e-03); Loss of SUMOylation at K884 (Pr = 0.21 | P = 0.03); Loss of Ubiquitylation at K884 (Pr = 0.16 | P = 0.03), ELME000085|PS00008,-
COL2A1_HUMAN,G504S,0.954,Gain of Phosphorylation at G504 (Pr = 0.39 | P = 6.7e-03); Gain of Loop (Pr = 0.27 | P = 0.02); Loss of Methylation at R509 (Pr = 0.11 | P = 0.03), ELME000136|ELME000155|ELME000159,-
COL2A1_HUMAN,R940Q,0.437,-,-,-
COL2A1_HUMAN,G1176V,0.963,Loss of B-factor (Pr = 0.29 | P = 0.01); Gain of Acetylation at K1174 (Pr = 0.24 | P = 0.01); Loss of Methylation at K1174 (Pr = 0.24 | P = 2.5e-03); Gain of SUMOylation at K1174 (Pr = 0.20 | P = 0.03); Gain of Ubiquitylation at K1174 (Pr = 0.18 | P = 0.02); Gain of O-linked glycosylation at S1172 (Pr = 0.13 | P = 0.04), ELME000321,-
COL2A1_HUMAN,I1450T,0.744,Altered Transmembrane protein (Pr = 0.31 | P = 1.2e-04); Altered Ordered interface (Pr = 0.31 | P = 0.01); Loss of Strand (Pr = 0.27 | P = 0.02); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Gain of Acetylation at K1447 (Pr = 0.19 | P = 0.05); Altered Stability (Pr = 0.15 | P = 0.02), ELME000053|ELME000064|ELME000146|ELME000220|PS00006,-
COL2A1_HUMAN,G771V,0.976,Loss of B-factor (Pr = 0.27 | P = 0.02); Loss of Acetylation at K773 (Pr = 0.26 | P = 1.0e-02); Loss of Methylation at K773 (Pr = 0.25 | P = 2.4e-03); Gain of SUMOylation at K773 (Pr = 0.21 | P = 0.02); Altered Metal binding (Pr = 0.20 | P = 0.04); Loss of Ubiquitylation at K773 (Pr = 0.17 | P = 0.03), None,-
COL2A1_HUMAN,G318R,0.960,Loss of B-factor (Pr = 0.29 | P = 0.01); Altered Metal binding (Pr = 0.18 | P = 0.05), ELME000070|ELME000136,-
COL2A1_HUMAN,G465S,0.944,Loss of Acetylation at K464 (Pr = 0.30 | P = 4.0e-03); Gain of Loop (Pr = 0.28 | P = 0.02); Altered Disordered interface (Pr = 0.27 | P = 0.04); Loss of Methylation at K464 (Pr = 0.25 | P = 1.8e-03); Gain of SUMOylation at K464 (Pr = 0.25 | P = 8.9e-03), ELME000002,-
COL2A1_HUMAN,G222V,0.968,Altered Disordered interface (Pr = 0.27 | P = 0.05); Loss of B-factor (Pr = 0.26 | P = 0.04), None,-
COL2A1_HUMAN,G546S,0.927,Loss of Methylation at K542 (Pr = 0.27 | P = 1.3e-03); Loss of B-factor (Pr = 0.26 | P = 0.05); Loss of Acetylation at K542 (Pr = 0.24 | P = 0.02); Loss of SUMOylation at K542 (Pr = 0.19 | P = 0.04); Loss of Ubiquitylation at K542 (Pr = 0.17 | P = 0.02), ELME000155,-
COL2A1_HUMAN,G453A,0.938,Altered Disordered interface (Pr = 0.28 | P = 0.04); Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Methylation at K452 (Pr = 0.23 | P = 3.5e-03); Gain of SUMOylation at K452 (Pr = 0.21 | P = 0.03); Gain of Ubiquitylation at K452 (Pr = 0.16 | P = 0.04), ELME000173,-
COL2A1_HUMAN,G144V,0.955,Loss of B-factor (Pr = 0.31 | P = 5.7e-03); Loss of Methylation at R149 (Pr = 0.28 | P = 1.0e-03); Loss of Acetylation at K143 (Pr = 0.26 | P = 9.7e-03); Gain of SUMOylation at K140 (Pr = 0.26 | P = 6.2e-03); Gain of Ubiquitylation at K143 (Pr = 0.16 | P = 0.04), None,-
COL2A1_HUMAN,G1128V,0.962,Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of SUMOylation at K1130 (Pr = 0.23 | P = 0.02); Loss of Methylation at K1130 (Pr = 0.12 | P = 0.03), ELME000146,-
COL2A1_HUMAN,G921R,0.961,Loss of B-factor (Pr = 0.31 | P = 5.9e-03); Gain of Acetylation at K925 (Pr = 0.30 | P = 3.9e-03); Loss of Methylation at K925 (Pr = 0.27 | P = 1.2e-03); Gain of SUMOylation at K925 (Pr = 0.19 | P = 0.04); Loss of O-linked glycosylation at S923 (Pr = 0.16 | P = 0.03), ELME000006|ELME000062|ELME000135|ELME000239,-
COL2A1_HUMAN,G855V,0.964,Loss of Methylation at K857 (Pr = 0.28 | P = 9.1e-04); Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Acetylation at K857 (Pr = 0.23 | P = 0.02); Loss of SUMOylation at K857 (Pr = 0.23 | P = 0.02); Gain of Ubiquitylation at K857 (Pr = 0.18 | P = 0.02); Altered Metal binding (Pr = 0.12 | P = 0.04), None,-
COL2A1_HUMAN,G492V,0.970,Loss of B-factor (Pr = 0.28 | P = 0.02); Gain of Loop (Pr = 0.26 | P = 0.05); Gain of SUMOylation at K490 (Pr = 0.26 | P = 6.0e-03); Loss of Methylation at K490 (Pr = 0.25 | P = 1.8e-03); Loss of Acetylation at K490 (Pr = 0.24 | P = 0.02), ELME000100|ELME000108,-
COL2A1_HUMAN,G750V,0.950,Loss of Methylation at R755 (Pr = 0.12 | P = 0.03), None,-
COL2A1_HUMAN,G381D,0.965,Gain of Loop (Pr = 0.30 | P = 4.6e-03); Loss of Methylation at R383 (Pr = 0.21 | P = 5.5e-03), ELME000293,-
COL2A1_HUMAN,G678R,0.937,Loss of B-factor (Pr = 0.32 | P = 4.0e-03); Loss of Loop (Pr = 0.31 | P = 4.9e-03); Loss of Acetylation at K679 (Pr = 0.29 | P = 4.7e-03); Loss of Methylation at K679 (Pr = 0.27 | P = 1.2e-03); Gain of SUMOylation at K679 (Pr = 0.22 | P = 0.02), ELME000093|ELME000102|PS00008|PS00009,-
COL2A1_HUMAN,L667F,0.445,-,-,-
COL2A1_HUMAN,G408D,0.970,Gain of Loop (Pr = 0.28 | P = 0.01); Loss of O-linked glycosylation at S407 (Pr = 0.14 | P = 0.04); Altered Metal binding (Pr = 0.13 | P = 0.03), ELME000085|ELME000239|PS00008,-
COL2A1_HUMAN,G453V,0.962,Loss of B-factor (Pr = 0.28 | P = 0.02); Altered Disordered interface (Pr = 0.27 | P = 0.05); Loss of Methylation at K452 (Pr = 0.24 | P = 2.5e-03); Gain of SUMOylation at K452 (Pr = 0.21 | P = 0.03), ELME000173,-
COL2A1_HUMAN,G1062C,0.960,Altered Disordered interface (Pr = 0.31 | P = 0.02); Loss of Methylation at R1058 (Pr = 0.14 | P = 0.02), ELME000052|ELME000155,-
COL2A1_HUMAN,G381R,0.964,Loss of Loop (Pr = 0.32 | P = 3.7e-03); Gain of Methylation at R383 (Pr = 0.21 | P = 3.8e-03); Gain of ADP-ribosylation at G381 (Pr = 0.19 | P = 0.05); Gain of O-linked glycosylation at T380 (Pr = 0.15 | P = 0.03), None,-
COL2A1_HUMAN,G345D,0.973,Loss of Methylation at R344 (Pr = 0.25 | P = 2.0e-03); Gain of B-factor (Pr = 0.24 | P = 0.04), None,-
COL2A1_HUMAN,G444D,0.967,Gain of Loop (Pr = 0.30 | P = 5.4e-03); Loss of B-factor (Pr = 0.26 | P = 0.04), ELME000052|ELME000293,-
COL2A1_HUMAN,G903S,0.936,Loss of Methylation at R904 (Pr = 0.13 | P = 0.02), ELME000097|ELME000155,-
COL2A1_HUMAN,G1173R,0.959,Loss of Acetylation at K1174 (Pr = 0.34 | P = 2.5e-03); Loss of Loop (Pr = 0.29 | P = 8.2e-03); Loss of B-factor (Pr = 0.27 | P = 0.02); Loss of Methylation at K1174 (Pr = 0.26 | P = 1.6e-03); Gain of SUMOylation at K1174 (Pr = 0.21 | P = 0.02); Gain of ADP-ribosylation at G1173 (Pr = 0.20 | P = 0.03); Loss of Ubiquitylation at K1174 (Pr = 0.18 | P = 0.02), ELME000006|ELME000085|ELME000102|ELME000321|PS00005|PS00006,-
COL2A1_HUMAN,G1155V,0.950,Loss of B-factor (Pr = 0.28 | P = 0.02); Loss of O-linked glycosylation at S1154 (Pr = 0.12 | P = 0.05), ELME000085|ELME000155,-
COL2A1_HUMAN,R1192C,0.590,Loss of Methylation at R1190 (Pr = 0.30 | P = 5.1e-04); Altered Disordered interface (Pr = 0.29 | P = 0.03); Loss of B-factor (Pr = 0.28 | P = 0.02); Gain of Loop (Pr = 0.28 | P = 0.01); Loss of ADP-ribosylation at R1192 (Pr = 0.27 | P = 7.1e-03), ELME000012|ELME000085,-
COL2A1_HUMAN,G396V,0.953,Loss of B-factor (Pr = 0.32 | P = 5.1e-03); Loss of Methylation at R392 (Pr = 0.19 | P = 7.8e-03), ELME000005|ELME000136|ELME000155|ELME000159|ELME000358,-
COL2A1_HUMAN,G561S,0.963,Gain of Proteolytic cleavage at R560 (Pr = 0.14 | P = 0.02); Loss of Methylation at R560 (Pr = 0.12 | P = 0.03), ELME000146|ELME000173,-
COL2A1_HUMAN,G1074S,0.942,Gain of Loop (Pr = 0.29 | P = 9.3e-03); Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of O-linked glycosylation at S1075 (Pr = 0.14 | P = 0.04), ELME000136|ELME000155|ELME000159,-
COL2A1_HUMAN,G1182D,0.964,Altered Disordered interface (Pr = 0.28 | P = 0.04); Gain of Loop (Pr = 0.27 | P = 0.03), ELME000155,-
COL2A1_HUMAN,G1179R,0.949,Loss of Loop (Pr = 0.28 | P = 0.02); Gain of Acetylation at K1174 (Pr = 0.28 | P = 5.8e-03); Loss of Methylation at K1174 (Pr = 0.26 | P = 1.7e-03); Gain of SUMOylation at K1174 (Pr = 0.20 | P = 0.04); Loss of Ubiquitylation at K1174 (Pr = 0.18 | P = 0.02), None,-
COL2A1_HUMAN,A145V,0.104,-,-,-
COL2A1_HUMAN,G267D,0.959,Gain of Loop (Pr = 0.27 | P = 0.04); Loss of Acetylation at K262 (Pr = 0.27 | P = 7.1e-03); Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Methylation at K262 (Pr = 0.26 | P = 1.5e-03); Loss of SUMOylation at K262 (Pr = 0.22 | P = 0.02); Gain of Ubiquitylation at K262 (Pr = 0.16 | P = 0.03), ELME000155,-
COL2A1_HUMAN,G690R,0.965,Loss of Loop (Pr = 0.28 | P = 0.02), ELME000149,-
COL2A1_HUMAN,G483R,0.969,Loss of B-factor (Pr = 0.27 | P = 0.02); Gain of Methylation at G483 (Pr = 0.15 | P = 0.01), None,-
COL2A1_HUMAN,G219E,0.966,, None,-
COL2A1_HUMAN,G654S,0.949,Loss of Methylation at R653 (Pr = 0.17 | P = 0.01), None,-
COL2A1_HUMAN,G984R,0.971,Loss of Loop (Pr = 0.31 | P = 4.6e-03); Altered Disordered interface (Pr = 0.30 | P = 0.02); Gain of Methylation at R980 (Pr = 0.12 | P = 0.03); Loss of Pyrrolidone carboxylic acid at Q979 (Pr = 0.05 | P = 0.04), ELME000155,-
COL2A1_HUMAN,G1017V,0.970,Loss of B-factor (Pr = 0.33 | P = 2.3e-03); Gain of O-linked glycosylation at S1013 (Pr = 0.16 | P = 0.03); Loss of Methylation at R1016 (Pr = 0.14 | P = 0.02), ELME000155|ELME000259,-
COL2A1_HUMAN,C1323W,0.968,Altered Metal binding (Pr = 0.73 | P = 8.2e-04); Loss of Disulfide linkage at C1323 (Pr = 0.42 | P = 5.1e-04); Altered Transmembrane protein (Pr = 0.31 | P = 1.2e-04); Altered Ordered interface (Pr = 0.28 | P = 0.04); Gain of Strand (Pr = 0.26 | P = 0.04); Gain of Catalytic site at C1323 (Pr = 0.10 | P = 0.04); Gain of GPI-anchor amidation at N1327 (Pr = 0.01 | P = 0.03), None,-
COL2A1_HUMAN,G519S,0.968,Altered Disordered interface (Pr = 0.27 | P = 0.04); Gain of Loop (Pr = 0.26 | P = 0.04); Loss of Methylation at R515 (Pr = 0.19 | P = 7.8e-03), ELME000202,-
COL2A1_HUMAN,G372R,0.961,Loss of Loop (Pr = 0.28 | P = 0.01); Loss of Methylation at K374 (Pr = 0.28 | P = 8.5e-04); Loss of B-factor (Pr = 0.26 | P = 0.03); Loss of Acetylation at K374 (Pr = 0.22 | P = 0.03); Loss of Ubiquitylation at K374 (Pr = 0.21 | P = 5.8e-03), PS00008,-
COL2A1_HUMAN,G1131A,0.940,Gain of SUMOylation at K1130 (Pr = 0.23 | P = 0.01); Loss of Methylation at K1130 (Pr = 0.12 | P = 0.03), ELME000146,-
COL2A1_HUMAN,G516D,0.975,Altered Disordered interface (Pr = 0.27 | P = 0.04); Gain of Loop (Pr = 0.27 | P = 0.02); Loss of Methylation at R515 (Pr = 0.23 | P = 3.5e-03), None,-
COL2A1_HUMAN,G780R,0.968,Loss of Acetylation at K781 (Pr = 0.36 | P = 1.9e-03); Loss of B-factor (Pr = 0.29 | P = 0.02); Altered Disordered interface (Pr = 0.27 | P = 0.04); Loss of Methylation at K781 (Pr = 0.24 | P = 2.6e-03); Gain of SUMOylation at K781 (Pr = 0.24 | P = 0.01); Altered Metal binding (Pr = 0.19 | P = 0.05), ELME000102,-
COL2A1_HUMAN,G348D,0.969,Gain of Loop (Pr = 0.26 | P = 0.05); Gain of B-factor (Pr = 0.25 | P = 0.03); Loss of Methylation at R344 (Pr = 0.21 | P = 5.4e-03), None,-
COL2A1_HUMAN,G759S,0.952,Altered Disordered interface (Pr = 0.27 | P = 0.05); Gain of Loop (Pr = 0.27 | P = 0.02); Loss of Methylation at K764 (Pr = 0.26 | P = 1.8e-03); Loss of Acetylation at K764 (Pr = 0.24 | P = 0.02); Loss of Ubiquitylation at K764 (Pr = 0.18 | P = 0.02), ELME000051,-
COL2A1_HUMAN,G774S,0.961,Gain of Phosphorylation at G774 (Pr = 0.51 | P = 3.3e-03); Loss of Acetylation at K773 (Pr = 0.28 | P = 5.7e-03); Loss of B-factor (Pr = 0.26 | P = 0.03); Loss of Methylation at K773 (Pr = 0.25 | P = 2.0e-03); Loss of SUMOylation at K773 (Pr = 0.21 | P = 0.03); Altered Metal binding (Pr = 0.19 | P = 0.04); Loss of Ubiquitylation at K773 (Pr = 0.17 | P = 0.03), ELME000136|ELME000159,-
COL2A1_HUMAN,G831R,0.955,Loss of B-factor (Pr = 0.29 | P = 0.01), ELME000135|ELME000155,-
COL2A1_HUMAN,A1051T,0.346,-,-,-
COL2A1_HUMAN,V1331I,0.138,-,-,-
COL2A1_HUMAN,P952T,0.146,-,-,-
COL2A1_HUMAN,G1405S,0.764,Altered Ordered interface (Pr = 0.36 | P = 3.3e-03); Altered Metal binding (Pr = 0.29 | P = 0.02); Gain of Relative solvent accessibility (Pr = 0.29 | P = 0.01); Altered Transmembrane protein (Pr = 0.26 | P = 1.0e-03); Loss of Methylation at K1408 (Pr = 0.13 | P = 0.02), ELME000313,-
COL2A1_HUMAN,T9S,0.111,-,-,-
COL2A1_HUMAN,I2P,0.733,Loss of Helix (Pr = 0.28 | P = 0.02); Altered Stability (Pr = 0.21 | P = 0.01); Loss of N-terminal acetylation at M1 (Pr = 0.07 | P = 2.6e-03); Altered Signal peptide (Pr = 0.06 | P = 2.8e-03), ELME000355,-
COL2A1_HUMAN,A6T,0.198,-,-,-
COL2A1_HUMAN,P7A,0.147,-,-,-
COL2A1_HUMAN,Q8K,0.454,-,-,-
COL2A1_HUMAN,Q8P,0.715,Loss of Helix (Pr = 0.29 | P = 0.01); Altered Signal peptide (Pr = 0.26 | P = 3.5e-04), ELME000052|ELME000149|PS00008,-
COL2A1_HUMAN,Q8R,0.313,-,-,-
COL2A1_HUMAN,V17L,0.297,-,-,-
COL2A1_HUMAN,G25A,0.383,-,-,-
COL2A1_HUMAN,G25K,0.556,Loss of Pyrrolidone carboxylic acid at Q24 (Pr = 0.25 | P = 7.5e-04); Altered Signal peptide (Pr = 0.06 | P = 1.9e-03), None,-
